Rhythm Biosciences Appoints CEO; Shares Down 3%

Rhythm Biosciences (ASX:RHY) appointed David Atkins as chief executive, effective May 13. Atkins has experience across a broad range of life sciences and healthcare disciplines, according to a Wednesd

MT NewswiresApr 23 21:39 ET

Rhythm Biosciences Receives AU$2.5 Million Under Rights Issue; Shares Up 3%

Rhythm Biosciences (ASX:RHY) received AU$2.5 million under its nonrenounceable rights issue. Shares and options under the rights issue will be allotted March 21 and start trading March 22, according t

MT NewswiresMar 20 23:51 ET

Rhythm Biosciences Seeks to Raise AU$6.6 Million Via Rights Offer; Shares Fall 29%

Rhythm Biosciences (ASX:RHY) is undertaking a 3-for-10 nonrenounceable rights issue at AU$0.10 apiece to raise about AU$6.6 million. Proceeds will be used to transition the current ColoSTAT test to th

MT NewswiresFeb 9 00:12 ET

Rhythm Biosciences Identifies Lung Cancer Biomarkers From Blood Samples; Shares Fall 6%

Rhythm Biosciences (ASX:RHY) identified potential lung cancer biomarkers following a study conducted by bioanalytical partner the Baker Institute, the diagnostic firm said on Friday. The study analyze

MT NewswiresNov 23, 2023 22:13 ET

Rhythm Biosciences Receives First Tranche of R&D Tax Rebate

Medical diagnostics company Rhythm Biosciences (ASX:RHY) received the first tranche of AU$1.7 million in research and development tax incentive. The second tranche of the tax rebate is expected in 202

MT NewswiresNov 14, 2023 02:41 ET

Rhythm Biosciences' Breast Cancer Diagnostic Test Shows Positive Results

Rhythm Biosciences (ASX:RHY), in an update on its cancer diagnostics technology platform expansion program, said it has, along with Agilex Biolabs, identified four biomarkers that "exhibit a strong co

MT NewswiresSep 22, 2023 09:09 ET